METTL14 is decreased and regulates m6 A modification of α-synuclein in Parkinson's disease

Honghu He1, Qinxin Zhang1, Jiajia Liao1,2

  • 1Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.

PubMed

Insights

N6-methyladenosine (m6A) levels are lower in Parkinson's disease (PD) patients. METTL14, a key m6A regulator, shows potential as a diagnostic biomarker for PD by targeting alpha-synuclein mRNA.

Area of Science:

  • Epigenetics and RNA modifications
  • Neurodegenerative diseases
  • Molecular mechanisms of disease

Background:

  • N6-methyladenosine (m6A) is a prevalent mRNA modification involved in various biological processes.
  • The role of m6A modification in Parkinson's disease (PD) pathogenesis is not well understood.
  • Investigating m6A's role could reveal novel insights into PD mechanisms and potential therapeutic targets.

Purpose of the Study:

  • To investigate the role and underlying mechanisms of m6A modification in Parkinson's disease.
  • To assess the diagnostic potential of m6A regulators as biomarkers for PD.
  • To elucidate the specific molecular pathway involving m6A in PD pathogenesis.

Main Methods:

  • Recruitment of 86 PD patients and 86 healthy controls for a pilot multicenter cohort study.
  • Quantification of m6A levels and modulators (METTL3, METTL14, YTHDF2) in peripheral blood mononuclear cells.
  • In vitro mechanistic studies including RNA immunoprecipitation, stability assays, gene manipulation, and western blotting.

Main Results:

  • Significantly lower mRNA levels of m6A, METTL3, METTL14, and YTHDF2 were observed in PD patients compared to controls.
  • METTL14 was identified as the primary factor in abnormal m6A modification and demonstrated diagnostic capability for PD, especially with alpha-synuclein.
  • METTL14 targets and downregulates alpha-synuclein (α-syn) expression by increasing m6A modification and decreasing the stability of α-syn mRNA.

Conclusions:

  • METTL14 is a key regulator of m6A modification in Parkinson's disease.
  • METTL14 shows promise as a novel diagnostic biomarker for PD, potentially in combination with plasma α-synuclein.
  • METTL14-mediated m6A modification of α-syn mRNA, recognized by YTHDF2, represents a crucial mechanism in PD pathogenesis.